Overview

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Status:
Recruiting
Trial end date:
2021-10-19
Target enrollment:
Participant gender:
Summary
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Lumosa Therapeutics Co., Ltd.
Treatments:
Apixaban
Aspirin
Clopidogrel
Dabigatran